(NP (NP (NP (NN Cortisol) (NN receptor) (NN resistance)) (: :)) (NP (NP (DT the) (NN variability)) (PP (IN of) (NP (PRP$ its) (NP-COOD (NP (JJ clinical) (NN presentation)) (CC and) (NP (NP (NN response)) (PP (TO to) (NP (NN treatment))))))) (. .)))
(S (NP-SBJ-33 (JJ Primary) (-LRB- -LRB-) (JJ partial) (-RRB- -RRB-) (NN cortisol) (NN receptor) (NN resistance)) (VP (VBD was) (ADVP-TMP (RB previously)) (VP (VBN reported) (NP (-NONE- *-33)) (PP (IN in) (NP (NP (DT a) (NN total)) (PP (IN of) (NP-COOD (NP (CD 7) (NNS patients)) (CC and) (NP (CD 14) (JJ asymptomatic) (NN family) (NNS members)))))))) (. .))
(S (NP-SBJ-34 (PRP$ Its) (NN occurrence)) (VP (VBZ is) (VP (VBN considered) (S (NP-SBJ (-NONE- *-34)) (VP (TO to) (VP (VB be) (ADJP-PRD (RB extremely) (JJ rare))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP-SBJ (PRP we)) (VP (VBP report) (PP (IN on) (NP (NP (NP (CD 6) (NNS patients)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD 2) (NNS males)) (CC and) (NP (CD 4) (NNS females))) (-RRB- -RRB-))) (PP (IN with) (NP (DT the) (NN syndrome)))))) (. .))
(S (NP-SBJ (DT The) (JJ first) (JJ male) (NN patient)) (VP (VBD presented) (PP (IN with) (NP (JJ mild) (NN hypertension)))) (. .))
(S (NP-SBJ (NN Hydrochlorothiazide) (NN therapy)) (VP (VBD resulted) (PP (IN in) (NP (JJ life-threatening) (NN hypokalemia)))) (. .))
(S (NP-SBJ (DT The) (JJ second) (JJ male) (NN patient)) (VP (VBD had) (NP (NP (JJ slight) (NN hypertension)) (PP (IN without) (NP (NN hypokalemia))))) (. .))
(S (NP-SBJ (DT All) (CD four) (JJ female) (NNS patients)) (VP (VBD presented) (PP (IN between) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (QP (CD 20-30)) (NN yr))))) (PP (IN with) (NP-COOD (NP (NN acne)) (, ,) (NP (NN hirsutism)) (, ,) (CC and) (NP (JJ irregular) (NNS menstruations))))) (. .))
(S (NP-SBJ (NP (JJ Low) (NN dose) (NN dexamethasone) (NN therapy)) (PRN (-LRB- -LRB-) (NP (QP (CD 1-1.5)) (NN (day mg))) (-RRB- -RRB-))) (VP (VBD was) (PP-PRD (IN of) (NP (JJ clinical) (NN benefit))) (PP (IN in) (NP (DT these) (NNS patients)))) (. .))
(S (NP-SBJ (DT All) (NNS patients)) (VP (VBD showed) (NP (NP (JJ insufficient) (NN suppression)) (PP (IN of) (NP (NN serum) (NN cortisol) (NNS concentrations)))) (PP (IN in) (NP (DT the) (JJ overnight) (JJ 1-mg) (NN dexamethasone) (NN test)))) (. .))
(S (NP-SBJ (NP (DT The) (JJ diurnal) (NN rhythm)) (PP (IN of) (NP-COOD (NP (NN ACTH)) (CC and) (NP (NN cortisol))))) (VP (VBD was) (ADJP-PRD (JJ intact)) (, ,) (PP (IN albeit) (FRAG (PP (IN at) (NP (DT an) (JJ elevated) (NN level)))))) (. .))
(S (NP-SBJ (EX There)) (VP (VBD was) (NP (NP-PRD (DT a) (JJ normal) (NN increase)) (PP (IN in) (NP-COOD (NP (NN ACTH)) (, ,) (NP (NN cortisol)) (, ,) (CC and) (NP (NN GH))))) (-LRB- -LRB-) (PP (IN except) (FRAG (PP (IN in) (NP (CD one) (JJ obese) (NN patient))))) (-RRB- -RRB-) (PP (IN in) (NN response) (TO to) (NP (JJ insulin-induced) (NN hypoglycemia))) (, ,) (SBAR (IN while) (S (NP-SBJ-35 (NN cortisol) (NN production)) (VP (VBD was) (VP (JJ elevated) (NP (-NONE- *-35)) (PP (IN in) (NP (CD three) (NNS patients)))))))) (. .))
(S (NP-SBJ-36 (VBG Circulating) (JJ adrenal) (NN androgen) (NNS levels)) (VP (VBD were) (VP (VBN increased) (NP (-NONE- *-36)) (PP (IN in) (NP (DT all) (NNS patients))))) (. .))
(S (NP-SBJ-37 (NN Glucocorticoid) (NNS receptors)) (VP (VBD were) (VP (VBN investigated) (NP (-NONE- *-37)) (PP (IN in) (NP (DT a) (JJ whole) (NN cell) (NN dexamethasone) (NN binding) (NN assay))) (PP (IN in) (NP (JJ mononuclear) (NNS leukocytes))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ first) (JJ male) (NN patient))) (, ,) (NP-SBJ (NP (DT the) (NN number)) (PP (IN of) (NP (NNS receptors)))) (VP (VBD was) (ADJP-PRD (RB very) (JJ low)) (, ,) (SBAR (IN while) (S (NP-SBJ (DT the) (NN affinity)) (VP (VBD was) (ADJP-PRD (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (NNS controls)))))))))) (. .))
(S (NP-SBJ-38 (NP (DT A) (JJ lowered) (NN affinity)) (PP (TO to) (NP (NN dexamethasone)))) (VP (VBD was) (VP (VBN found) (NP (-NONE- *-38)) (PP (IN in) (NP (CD one) (JJ female) (NN patient))) (, ,) (SBAR (IN while) (S (NP-SBJ-39 (NP (DT a) (JJ lowered) (NN number)) (PP (IN of) (NP (NNS receptors)))) (VP (VBD was) (VP (VBN found) (NP (-NONE- *-39)) (PP (IN in) (NP (CD three) (NNS patients))))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ second) (JJ male) (NN patient))) (, ,) (NP-SBJ-40 (DT no) (NNS abnormalities)) (VP (VBD were) (VP (VBN found) (NP (-NONE- *-40)))) (. .))
(S (PP (IN As) (NP (NP (DT a) (NN bioassay)) (PP (IN for) (NP (NN glucocorticoid) (NN action))))) (NP-SBJ (PRP we)) (ADVP (RB also)) (VP (VBD measured) (NP (NP (NN dexamethasone) (NN suppressibility)) (PP (IN of) (NP (NP (JJ mitogen-stimulated) (NN incorporation)) (PP (IN of) (NP (NN -LCB-3H-RCB-thymidine))) (PP (IN in) (NP (JJ mononuclear) (NNS leukocytes))))))) (. .))
(S (PP (IN In) (NP (NP (DT the) (JJ male) (NN patient)) (PP (IN with) (NP (JJ normal) (NN receptor) (NN status))))) (, ,) (NP-SBJ (NP (NN dexamethasone) (NN suppressibility)) (PP (IN of) (NP (NN -LCB-3H-RCB-thymidine) (NN incorporation)))) (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (JJ healthy) (NNS controls)))))) (PP (IN with) (NN respect) (TO to) (NP-COOD (CC both) (NP (JJ maximal) (NN suppression)) (CC and) (NP (NN IC50))))) (. .))
(S (NP-SBJ (JJ Partial) (NN cortisol) (NN receptor) (NN resistance)) (VP (MD might) (VP (VB be) (ADJP-PRD (ADJP (RBR less) (JJ rare)) (SBAR (IN than) (FRAG (VP (ADVP-TMP (RB previously)) (VBN thought))))))) (. .))
(S (PP (IN In) (NP (NP (DT the) (CD six) (NNS patients)) (VP (VBN presented) (NP (-NONE- *))))) (, ,) (NP-SBJ-41 (QP (IN at) (JJS least) (CD three)) (JJ different) (NNS forms)) (VP (MD can) (VP (VB be) (VP (VBN recognized) (NP (-NONE- *-41))))) (. .))
(S (NP-SBJ (NP (NN Therapy)) (PP (IN with) (NP (NN dexamethasone)))) (VP (VBD was) (ADJP-PRD (JJ successful)) (PP (IN in) (NP (NP (JJ female) (NNS patients)) (PP (IN with) (NP-COOD (NP (NN acne)) (CC and) (NP (NN hirsutism)))))) (, ,) (SBAR (IN as) (S (NP-SBJ-42 (NP (DT the) (JJ secondary) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (JJ adrenal) (NNS androgens)))))) (VP (VBD was) (ADVP (RB effectively)) (VP (VBN controlled) (NP (-NONE- *-42))))))) (. .))
